Tagged with S

Opinion Axel Schumacher, co-founder and chief scientific officer of Shivom, a data-driven next generation precision-medicine company in the blockchain space, calls for Pharma to leverage big-data on a global level to ensure all patients have a therapy option.    The key to success for pharma players is to sponsor the accumulation of…

Korea Paul Henry Huibers, president of Lilly Korea discusses Lilly’s strong double-digit growth following a challenging period of restructuring. Huibers offers his opinion on the pricing difficulties within the Korean market, emphasizing the importance of volume over price. He also concludes that Korea should focus on establishing itself as a leader…

Korea The South Korean government has designated the promotion of artificial intelligence (AI)-based drug development and healthcare innovation as a national priority. This new policy aims to capitalise on Korea’s advanced technologies to drive the nation’s economic growth as well as better care for patients at home and abroad.   For…

Spain Luis Serrano, president of the Centre for Genomic Regulation (CRG) in Spain, gives an update on the Centre’s recent history and outlines the need for greater understanding of science and research within the Spanish political class.   When we enter discussions with the different political parties, I feel things are…

France Jean-Luc Belingard, president of FEFIS (Fédération Française des Industries de Santé – French Federation of the Health Industry), explains his role following up on the implementation of the CSIS (Conseil stratégique des industries de santé – Strategic council of the healthcare industry) and speaks out about the competitiveness of the…

Spain Carlos Rubió, executive president of Laboratorios Rubió, gives an overview of the company’s early years and his priorities now to make the company a larger player on the international scene. Furthermore, he highlights the need to increase the company´s size through JVs, possible M&As and US expansion, as well as…

Korea Uloff Münster, general manager of Merck Biopharma Korea provides his insights into the Korean healthcare system. Dr Münster also discusses the drug pricing situation in Korea and the potential for companies like Merck to utilize local partnerships.   We are in the process of preparing launches of our new molecules…

Spain Jordi Naval, CEO of Biocat, describes the evolution of the BioRegion of Catalonia as an increasingly relevant biotechnology hub in Spain and Europe. Naval also elaborates on the role of Biocat in tackling the challenge of translating basic research into functional innovation which can impact the healthcare ecosystem.   Now,…

Spain Gijs Jochems, general manager of Promega Biotech Iberica, a leading molecular biology solutions provider, speaks about the company’s business transformation to collaborate with diverse areas of the private sector. Jochems goes on to give his insights on the state of Spanish innovation and highlights how Promega uses its commitment to…

Spain Joachim Teubner, general manager of Aristo Pharma Iberia, a generics player, highlights the strategy that has helped the company realize rapid growth during a time in which the Spanish generic market has stagnated. Furthermore, he touches on the importance of self-manufacturing for generics companies and the future aspirations of the…

Top 10 2018 has been an exciting year in world health and our team has spanned the globe to bring you in-depth country reports and high profile interviews with leaders from the life science industry. Bringing you a diverse array of insights – from those spearheading the medical cannabis revolution to the…

UK The two Big Pharma giants today announced the merger between their consumer healthcare businesses, with the joint venture (JV) set to become the global market leader in over-the-counter (OTC) products with a market share of 7.3 percent.   This move will see GSK effectively split into two separate businesses –…